Ann: Q4 FY24 Investor Presentation, page-4

Mixed feelings.

Lot's of 'we are bullish' statements, but very scant on actual expectations of FY 2025 figures.

Probably the most important takeaways for me:

No current purchasers of Febridex in Australia

Good expansion of Febridex into the USA Student health market

Progress made on CLIA waiver

Progress made on re-imbursement coding - why that wasn't done before launch is baffling tbh.

I think it all depends on the Febridex uptake in the next FY (obviously) to see whether we will be 100% reliant on IP deals to keep the doors open.

If it takes off - so will the SP. It's that simple.

Overall - 6.5/10

Lots of bones, not too much meat.